Tirzepatide, a dual GIP/GLP-1 Receptor Co-Agonist for the Treatment of Type 2 Diabetes with Unmatched Effectiveness Regarding Glycaemic Control and Body Weight Reduction
Switching between vial sizes: what changes and what stays the same Many researchers start with smaller vials during the titration phase and move to larger vials once they find their maintenance dose
Funding source (industry vs
189 Subsequently, tirzepatide has been extensively investigated in the SURPASS program, a comprehensive development initiative targeting T2DM that is inadequately controlled by various glucose-lowering regimens, including lifestyle alone (SURPASS-1), 190 metformin monotherapy (SURPASS-2), 191 metformin with or without sodium-glucose co-transporter 2 inhibitors (SGLT2i) (SURPASS-3), 192 combination therapy including metformin, SGLT2i, and sulfonylureas (SURPASS-4), 193 insulin glargine with or without metformin (SURPASS-5), 88 and insulin lispro with basal insulin (SURPASS-6)
Easy to Use and Versatile Dissolves quickly in water or juice, with a natural taste that blends seamlessly into smoothies or other meals
A preclinical study in insulin resistant rats compared salivary antioxidants and oxidative stress products to those in plasma samples, exploring their diagnostic utility
